Prognostic implications of adverse events associated with CAR-T cell therapy: a population-based global observational study
This study was funded by the National Key Research and Development Program of China (2022YFC2804300), the National Natural Science Foundation of China (82222047, W2411079), the Science and Technology Commission of Shanghai Municipality (22XD1423100), and the Shanghai Municipal Health Commission (2022XD057, 2024ZZ1008).
Authors
- Hongyi Zhu (ORCID: https://orcid.org/0000-0001-9643-0790)
- Siying Wang (ORCID: https://orcid.org/0000-0003-0810-8828)
- Haojie Jin (ORCID: https://orcid.org/0000-0001-9295-1951)
- Yuan Ouyang (ORCID: https://orcid.org/0000-0003-2093-8795)
- Jinhao Li (ORCID: https://orcid.org/0000-0002-4812-3320)
- Hongye Wang (ORCID: https://orcid.org/0000-0002-6467-0316)
- Shunpeng Xing (ORCID: https://orcid.org/0000-0002-2796-0832)
- Weiming Shen (ORCID: https://orcid.org/0000-0001-5204-7992)
- Yunke Zhu (ORCID: https://orcid.org/0000-0002-7254-5478)
- Xiaoye Liu (ORCID: https://orcid.org/0000-0001-7753-2943)
- Zhe Li (ORCID: https://orcid.org/0000-0003-0225-7937)
- Zhen Sun
- Gang Chen (ORCID: https://orcid.org/0000-0001-7322-5292)
- Mengsi Liu
- Jianglong Guo (ORCID: https://orcid.org/0009-0009-4309-2535)
- Zhen Ye
Institutions
- Shanghai Jiao Tong University (CN)
- Wenzhou Medical University (CN)
- Renji Hospital (CN)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- Shanghai Cancer Institute (CN)
- First Affiliated Hospital of University of South China (CN)
- University of South China (CN)
Publication Details
- Journal
- EClinicalMedicine
- Published
- 2025-11-05
- DOI
- https://doi.org/10.1016/j.eclinm.2025.103623
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00